"Nearly all patients in southern Africa who have received treatment with the NNRTIs efavirenz or nevirapine would benefit from therapy with etravirine, a study published in the December 15th edition of the Journal of Acquired Immune Deficiency Syndromes suggests.
"Over 90% of patients previously exposed to efavirenz or nevirapine in the southern African treatment programmes will remain susceptible to etravirine despite prolonged exposure to first-line NNRTI-based regimens", comment the investigators."
Read more in Aidsmap, December 18, 2009.
0 comments:
Post a Comment